NDA 205109 · Vifor Fresenius
Velphoro
Ferric Oxyhydroxide · Oral · Phosphate Binder
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Nov 27, 2013
Approved uses
3
Original approval plus efficacy supplements
Registered trials
2
1 Phase 3, 0 recruiting
FAERS reports
3,046
2,193 serious, 1,293 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 26, 2026.
Velphoro is indicated for the control of serum phosphorus levels in adults and pediatric patients 6 years of age and older with chronic kidney disease (CKD) on dialysis. Velphoro is a phosphate binder indicated for the control of serum phosphorus levels in adult and pediatric patients 6 years of age and older with chronic kidney disease on dialysis. ( 1 )
Mechanism: In the aqueous environment of the GI tract, phosphate binding takes place by ligand exchange between hydroxyl groups and/or water in sucroferric oxyhydroxide and the phosphate in the diet. The bound phosphate is eliminated with feces. Both serum phosphorus levels and calcium-phosphorus product levels are reduced as a consequence of the reduced dietary phosphate absorption.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 13, 2026 Supplement 14 · Efficacy LetterLabel
- Jul 1, 2024 Supplement 9 · Efficacy LetterLabel
- Nov 27, 2013 Original approval · Type 5 - New Formulation or New Manufacturer LabelSummary ReviewLetter
2 products under this application
- VELPHORO · FERRIC OXYHYDROXIDE EQ 500MG IRON · TABLET, CHEWABLE, ORAL · Prescription
- VELPHORO · FERRIC OXYHYDROXIDE EQ 250MG IRON · TABLET, CHEWABLE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ferric Oxyhydroxide" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder TherapyPivotal-lookingCompleted
ArdelyxIndustry
NCT03824587 · 236 participants · Start Feb 28, 2019 · Primary completion Jul 17, 2019
Drug: Tenapanor; Placebo and 1 more · For: Hyperphosphatemia
Sites: Huntsville, Alabama; Pine Bluff, Arkansas; Beverly Hills, California · 48 sites in all
CMH Multan Institute of Medical SciencesGovernment (non-federal)
NCT06911034 · 60 participants · Start Feb 1, 2024 · Primary completion Jul 31, 2024
Drug: Iron Carboxymaltose; Iron Sucrose Injection · For: Iron Deficiency Anemia (IDA); Pregnancy
Sites: Multan, Pakistan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death1,146
- diarrhoea328
- nausea100
- constipation90
- hospitalisation88
- vomiting87
- faeces discoloured84
- drug intolerance68
- abdominal discomfort63
- off label use61
- product taste abnormal60
- abdominal pain53
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 25 |
| 2015 | 131 |
| 2016 | 135 |
| 2017 | 259 |
| 2018 | 284 |
| 2019 | 479 |
| 2020 | 661 |
| 2021 | 320 |
| 2022 | 114 |
| 2023 | 105 |
| 2024 | 195 |
| 2025 | 216 |
| 2026 | 122 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Velphoro (Sucroferric Oxyhydroxide)
2024 spending
$438M
Beneficiaries
38,351
156,980 claims
Per beneficiary
$11,432
$17.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $343,032,075 |
| 2021 | $380,608,096 |
| 2022 | $426,893,782 |
| 2023 | $465,812,435 |
| 2024 | $438,436,195 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis.
Zhuang B, Gan L, Liu B, et al. · Nephrol Dial Transplant 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Vifor Fresenius
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.